Differentiated Thyroid Cancer Clinical Trials

14 recruiting

Frequently Asked Questions

Common questions about Differentiated Thyroid Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

MelanomaNon-small Cell Lung CancerThyroid Cancer+10 more
Pfizer124 enrolled79 locationsNCT05538130
Recruiting
Not Applicable

Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers

Differentiated Thyroid Cancer
University College, London456 enrolled33 locationsNCT05604963
Recruiting
Not Applicable

F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer

Thyroid CancerDifferentiated Thyroid Cancer
Ankara University50 enrolled2 locationsNCT07436455
Recruiting
Not Applicable

Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer

Poorly Differentiated Thyroid CarcinomaAdvanced Thyroid CarcinomaRadioiodine-refractory Differentiated Thyroid Cancer
Zhejiang Provincial People's Hospital94 enrolled1 locationNCT07068542
Recruiting
Not Applicable

Iodine Uptake After a Low Iodine Diet

Differentiated Thyroid Cancer
University Medical Center Groningen25 enrolled1 locationNCT05599139
Recruiting
Phase 1

A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer

DTC - Differentiated Thyroid Cancer
Alpha Fusion Inc.38 enrolled1 locationNCT07287748
Recruiting
Phase 2

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

CancerPediatric CancerDifferentiated Thyroid Cancer+1 more
Children's Hospital of Philadelphia13 enrolled2 locationsNCT06458036
Recruiting

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Pediatric CancerPapillary Thyroid CancerDifferentiated Thyroid Cancer
Children's Hospital of Philadelphia32 enrolled9 locationsNCT05024929
Recruiting
Phase 2

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

CancerPediatric CancerDifferentiated Thyroid Cancer+1 more
Children's Hospital of Philadelphia13 enrolled5 locationsNCT05783323
Recruiting
Phase 2

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationAdvanced PDTC or ATC With NRAS Mutation
Fudan University40 enrolled1 locationNCT06970353
Recruiting
Early Phase 1

Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer

Radioiodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital20 enrolled1 locationNCT06898437
Recruiting
Phase 2

Pembrolizumab in High-risk Thyroid Cancer

Differentiated Thyroid Cancer
Istituti Clinici Scientifici Maugeri SpA25 enrolled1 locationNCT05852223
Recruiting

The EMIRATES Study

Differentiated Thyroid Cancer (DTC)
Royal Marsden NHS Foundation Trust15 enrolled1 locationNCT06855680
Recruiting

Nomogram for Predicting Difficult Transoral and Submental Thyroidectomy

Differentiated Thyroid Cancer
Shanghai 6th People's Hospital500 enrolled1 locationNCT06671184
Recruiting

Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer

Differentiated Thyroid CancerGender
Regina Elena Cancer Institute50 enrolled1 locationNCT05789667
Recruiting
Phase 2

Sacituzumab govitEcan in THYroid Cancers

Anaplastic Thyroid CancerDifferentiated Thyroid Cancer
Grupo Espanol de Tumores Neuroendocrinos42 enrolled11 locationsNCT06235216
Recruiting

Shared Care Thyroid Cancer Follow-up Utilizing Thyroid Cancer Assessment Reminder System (TCARS) Study - A Pilot Study.

Low Risk Differentiated Thyroid Cancer
Nova Scotia Health Authority60 enrolled1 locationNCT05510934
Recruiting
Not Applicable

Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment

Radiotherapy; ComplicationsDTC - Differentiated Thyroid CancerThyroid Stimulating; Hormone, C
Nanjing First Hospital, Nanjing Medical University30 enrolled1 locationNCT06405217
Recruiting
Not Applicable

Compare the Effects of NLSCP and Interactive ICT Supported HAP on Differentiate Diagnosed Thyroid Cancer Patients

Differentiated Thyroid Cancer
National Taiwan University Hospital380 enrolled1 locationNCT03757637
Recruiting

Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma

Lymph Node MetastasesDifferentiated Thyroid Cancer
Soroka University Medical Center250 enrolled5 locationsNCT05078853